{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:33Z","timestamp":1791472113336,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV) to SC formulations of IFX and VDZ in IBDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, retrospective study collected data of adult patients with Crohn's disease (CD) or ulcerative colitis (UC) switched to SC IFX or VDZ. The primary endpoint was clinical remission at 12\u2009months stratified based on timing of switch. A composite endpoint consisting of therapy discontinuation, reverse\u2010switch, need for steroids, and drug optimization was evaluated. A multivariate analysis investigated the association between patients' characteristics and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two hundred and thirty\u2010one patients (59% UC, 53% male, mean age 44\u2009\u00b1\u200915\u2009years, 68% IFX) from 13 centres were included. The switch occurred at Week 6 in a third of cases (36%). Median time to switch was 13\u2009months. Most patients switched to SC IFX and VDZ were in clinical remission at 3 (87% and 77%), 6 (86% and 83%) and 12 (63% and 60%) months. In the multivariate analysis, there was no difference in clinical remission rate at 12\u2009months; however, patients switched at Week 6 had a higher rate of experiencing any therapeutic changes at 3 (false discovery rate (FDR)\u2009=\u2009.002), 6 (FDR &lt;1\u2009\u00d7\u200910\n                      <jats:sup>\u221210<\/jats:sup>\n                      ) or 12\u2009months (FDR\u2009=\u2009.08). Clinical disease activity at baseline (only in UC) (FDR\u2009=\u2009.07) and previous exposure to biologics (FDR\u2009=\u2009.001) were risk factors for composite endpoint at 6 and 12\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SC IFX and VDZ are effective in daily clinical practice in IBD patients. Switching patients in remission reduces the risk of negative outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/eci.14283","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:40:45Z","timestamp":1720510845000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["An international multicentre study of\n                    <scp>SwiTching<\/scp>\n                    from Intravenous to subcutaneous\n                    <scp>inflixiMab<\/scp>\n                    and\n                    <scp>vEdolizumab<\/scp>\n                    in inflammatory bowel diseases: The\n                    <scp>TIME<\/scp>\n                    study"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-6995","authenticated-orcid":false,"given":"Ferdinando","family":"D'Amico","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Endoscopy IRCCS San Raffaele Hospital and Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Massimino","sequence":"additional","affiliation":[{"name":"Experimental Gastroenterology Unit, Division of Immunology, Transplantation and Infectious Disease IRCCS Ospedale San Raffaele  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy IRCCS San Raffaele Hospital and Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Dal Buono","sequence":"additional","affiliation":[{"name":"IBD Center IRCCS Humanitas Research Hospital  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gabbiadini","sequence":"additional","affiliation":[{"name":"IBD Center IRCCS Humanitas Research Hospital  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Caron","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Nancy University Hospital  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"},{"name":"INSERM, NGERE University of Lorraine  Nancy France"},{"name":"INFINY Institute Nancy University Hospital  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"},{"name":"FHU\u2010CURE Nancy University Hospital  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Moreira","sequence":"additional","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Silva","sequence":"additional","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Bosca\u2010Watts","sequence":"additional","affiliation":[{"name":"IBD Unit, Digestive Medicine Department Hospital Cl\u00ednico Universitario de Valencia  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Innocenti","sequence":"additional","affiliation":[{"name":"IBD Referral Centre, Clinical Gastroenterology Unit Careggi University Hospital  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Dragoni","sequence":"additional","affiliation":[{"name":"IBD Referral Centre, Clinical Gastroenterology Unit Careggi University Hospital  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[{"name":"IBD Center IRCCS Humanitas Research Hospital  Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Zilli","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy IRCCS San Raffaele Hospital and Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Furfaro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy IRCCS San Raffaele Hospital and Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[{"name":"IBD Center Gastroenterology Unit, Rho Hospital, ASST Rhodense  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS\u2010Princesa) Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Universidad Aut\u00f3noma de Madrid (UAM)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, Grupo de Investigaci\u00f3n Grupo de Investigaci\u00f3n Cl\u00ednica y Traslacional en Enfermedades Digestivas. Instituto de Investigaci\u00f3n Valdecilla (IDIVAL) Universidad de Cantabria  Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Michalopoulos","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology General Hospital of Athens \"G. Gennimatas\"  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Viazis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology \u2018Evangelismos\u2010Polykliniki\u2019 GHA  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerassimos J.","family":"Mantzaris","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology \u2018Evangelismos\u2010Polykliniki\u2019 GHA  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ellul","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Mater Dei Hospital  Msida Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS\u2010Princesa) Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Universidad Aut\u00f3noma de Madrid (UAM)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin\u2010Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Nancy University Hospital  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"},{"name":"INSERM, NGERE University of Lorraine  Nancy France"},{"name":"INFINY Institute Nancy University Hospital  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"},{"name":"FHU\u2010CURE Nancy University Hospital  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"},{"name":"Groupe Hospitalier priv\u00e9 Ambroise Par\u00e9\u2014Hartmann Paris IBD Center  Neuilly sur Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Center IRCCS Humanitas Research Hospital  Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Experimental Gastroenterology Unit, Division of Immunology, Transplantation and Infectious Disease IRCCS Ospedale San Raffaele  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy IRCCS San Raffaele Hospital and Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy San Camillo\u2010Forlanini Hospital  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Allocca","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy IRCCS San Raffaele Hospital and Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz180"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.022"},{"key":"e_1_2_11_6_1","unstructured":"Anon.Infliximab data sheet\u2014Cerca con Google. Accessed December 17 2023.https:\/\/www.google.it\/search?q=infliximab+data+sheet&sca_esv=591624743&sxsrf=AM9HkKl59GSpVOrGMp4PJ2yt5TVof1cPVQ%3A1702804490026&ei=Crx\u2010ZfSLAYmO9u8P0Jym6AQ&oq=infliximab+and+data+s&gs_lp=Egxnd3Mtd2l6LXNlcnAiFWluZmxpeGltYWIgYW5kIGRhdGEgcyoCCAEyBhAAGBYYHjIGEAAYFhgeMggQABgWGB4YD0jzU1D9N1iERHACeAGQAQCYAWagAZcGqgEDOS4xuAEByAEA\u2010AEBwgIKEAAYRxjWBBiwA8ICChAAGIAEGBQYhwLCAgUQABiABMICCBAAGIAEGMsB4gMEGAAgQYgGAZAGCA&sclient=gws\u2010wiz\u2010serp"},{"key":"e_1_2_11_7_1","unstructured":"Anon.Vedolizumab data sheet\u2014Cerca con Google. Accessed December 17 2023.https:\/\/www.google.it\/search?q=vedolizumab+data+sheet&sca_esv=591624743&sxsrf=AM9HkKlW3f\u2010xJPdY_6ljnojqUvtllxV44w%3A1702804505083&ei=Gbx\u2010ZcDOBPKE9u8P\u2010OCjsAk&oq=veedolizumdata+sheet&gs_lp=Egxnd3Mtd2l6LXNlcnAiFHZlZWRvbGl6dW1kYXRhIHNoZWV0KgIIADIGEAAYHhgNMggQABgIGB4YDUjiI1DrBli_GHACeAGQAQCYAYEBoAHBCaoBAzYuNrgBAcgBAPgBAcICBBAAGEfCAgoQABhHGNYEGLADwgIGEAAYBxgewgINEAAYgAQYDRixAxixA8ICBxAAGIAEGA3CAggQIRigARjDBMICChAhGKABGMMEGAriAwQYACBBiAYBkAYF&sclient=gws\u2010wiz\u2010serp"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.027"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab133"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247296"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.21105\/joss.03167"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686"},{"key":"e_1_2_11_14_1","unstructured":"Jr FEH functions CD contributed several functions and maintains latex. Hmisc: Harrell miscellaneous.2023Accessed March 1 2024.https:\/\/cran.r\u2010project.org\/web\/packages\/Hmisc\/"},{"key":"e_1_2_11_15_1","unstructured":"TherneauTM.TL original S\u2010>R port and R maintainer until Elizabeth a et\u00a0al. survival: survival analysis.2009Accessed March 11 2024.https:\/\/cran.r\u2010project.org\/web\/packages\/survival\/"},{"key":"e_1_2_11_16_1","unstructured":"KassambaraA KosinskiM BiecekP et\u00a0al.survminer: drawing survival curves using \u201cggplot2.\u201d.2021Accessed March 11 2024.https:\/\/cran.r\u2010project.org\/web\/packages\/survminer\/"},{"key":"e_1_2_11_17_1","article-title":"Subcutaneous infliximab [CT\u2010P13], a true biologic 2.0. Real clinical practice multicentre study","volume":"10","author":"Huguet JM","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.08.011"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac053"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-5084"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247657"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad166"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.07.011"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2176252"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17153"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17822"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.897936"},{"key":"e_1_2_11_28_1","article-title":"One\u2010year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study","volume":"30","author":"Hong SN","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_11_29_1","first-page":"1","article-title":"Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses","volume":"59","author":"Harno\u2010Tasihin J","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195669"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102849"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16311"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac009"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13387"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312307"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv096"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.122"},{"key":"e_1_2_11_38_1","unstructured":"AdminS.European Crohn's and colitis organisation\u2014ECCO\u2014P591 negative impact of high body mass index on the efficacy of anti\u2010TNF\u03b1 agents in patients with inflammatory bowel disease. Accessed June 4 2024.https:\/\/www.ecco\u2010ibd.eu\/publications\/congress\u2010abstracts\/item\/p591\u2010negative\u2010impact\u2010of\u2010high\u2010body\u2010mass\u2010index\u2010on\u2010the\u2010efficacy\u2010of\u2010anti\u2010tnf\u2010agents\u2010in\u2010patients\u2010with\u2010inflammatory\u2010bowel\u2010disease.html"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01252-z"},{"key":"e_1_2_11_40_1","article-title":"Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease","volume":"18","author":"Roblin X","year":"2023","journal-title":"J Crohns Colitis"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.14283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:28:22Z","timestamp":1737080902000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.14283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/eci.14283"],"URL":"https:\/\/doi.org\/10.1111\/eci.14283","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2024-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14283"}}